TRTL-913 (GABA-A positive allosteric modulator) Phase 2a for tinnitus

Trial details

Registry identifier: NCT07777549 on ClinicalTrials.gov
Phase: Phase 2a
Status: Not yet recruiting (est. start Sept 2026)
Sponsor: Tortugas Neuroscience
Planned enrollment: 100
Estimated completion: Aug 2027
Country: USA

Why this trial matters

One of only two Phase 2+ drug trials in the world targeting tinnitus as the primary indication. Note: Part A doses healthy volunteers; only Part B is in tinnitus patients. Tortugas launched April 2026 with $106M to develop the ex-Hansoh compound.

Related treatment evidence

See the current evidence for TRTL-913 (GABA-A modulator).

Trial statuses are verified against the ClinicalTrials.gov registry by our weekly automated check. A tracked trial is research in progress — inclusion is not a treatment recommendation, and only the study team can determine eligibility.